IOL Chemicals and Pharmaceuticals logo

IOL Chemicals and Pharmaceuticals financials: balance sheet, profit and loss, cash flow

NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap

IOL Chemicals and Pharmaceuticals Limited · Face value ₹2 · Listed Feb 1991 on BSE, Nov 2010 on NSE
Last close ₹179.36up ₹11.38 (6.77%)BSE ₹179.00

Share price at the NSE close on 27 Oct 2026. Previous close ₹167.98.

27 Oct: open ₹168.60, high ₹181.00, low ₹166.44

52-week range of traded prices to 27 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
Market cap
₹5,265 Cr1,024th largest listed
P/E
31.32
P/B
2.93
Dividend yield
0.56%
ROE
9.6%
ROCE
11.8%
Debt to equity
0.07
Volume, NSE
18,06,29342.0% delivered

IOL Chemicals and Pharmaceuticals' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.IOL Chemicals and Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
7114.2Mar 171,00128Mar 181,685237258Mar 191,89436156Mar 201,9674450Mar 212,18416644Mar 222,21714080Mar 232,13313533Mar 242,079101117Mar 252,319138132Mar 26
Peak revenue ₹2,319 Cr, year to Mar 2026; lowest ₹711 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
30.3%0.6%14.3%12.4%24.3%30.3%30.1%11.7%10.2%10.9%9.7%11.6%0.6%2.8%14.0%19.1%22.6%7.6%6.3%6.3%4.9%5.9%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 0.2% of operating profit in the first full year.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue2,319
  2. Materials and goods−1,487
  3. Employee costs−248
  4. Other expenses−315
  5. Operating profit269
  6. Depreciation−80
  7. Other income+21
  8. One-off items−11
  9. Finance costs−15
  10. Profit before tax184
  11. Tax−47
  12. Net profit138

What the company owns

  • Plant, investments and other assets₹1,411 Cr
  • Receivables₹603 Cr
  • Inventory₹371 Cr
  • Cash and bank₹198 Cr
  • Current investments₹4 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,798 Cr
  • Owed to suppliers₹483 Cr
  • Other liabilities₹174 Cr
  • Borrowings₹132 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.IOL Chemicals and Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 MayJun 2026Twelve monthsFiled 10 Aug
Revenue from operations7111,0011,6851,8941,9672,1842,2172,1332,0792,3192,524
6098771,2761,3211,3751,9281,9911,9011,8772,0502,213
Materials and goods bought4796951,0471,0651,1031,5711,5471,3971,3921,4871,601
Employee costs44–7897116141168201217248262
Other expenses86–150158157216275303269315350
Operating profit before depreciation102124410574592256227232202269310
Operating margin14.3%12.4%24.3%30.3%30.1%11.7%10.2%10.9%9.7%11.6%12.3%
Materials, % of revenue67.5%–62.1%56.2%56.1%71.9%69.8%65.5%66.9%64.1%63.4%
Employee costs, % of revenue6.2%–4.7%5.1%5.9%6.5%7.6%9.4%10.4%10.7%10.4%
Other expenses, % of revenue12.1%–8.9%8.4%8.0%9.9%12.4%14.2%12.9%13.6%13.9%
Depreciation and amortisation3030323639434663728082
Operating profit after depreciation7294377538553213180169130189229
Other income12101624322630222122
Finance costs67645121681616151514
Profit before one-off items and tax531336533571237189183138196237
One-off items––000−14000−11−11
Profit before tax531336533571223189183138184226
1499172127575047374757
Net profit428237361445166140135101138168
Other comprehensive income––−1−2−2−10−1−132
Total comprehensive income––235360442165140134100140170
Net margin0.6%2.8%14.0%19.1%22.6%7.6%6.3%6.3%4.9%5.9%6.7%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank.
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations318305350391473484565386582
282269311322402392468373529
Materials and goods bought231223248271325300370279414
Employee costs–––––22272535
Other expenses–––––70717080
Operating profit before depreciation363640707192971353
Operating margin11.4%11.8%11.3%17.8%15.0%18.9%17.2%3.3%9.0%
Materials, % of revenue–––––62.0%65.5%72.3%71.1%
Employee costs, % of revenue–––––4.6%4.8%6.4%6.0%
Other expenses, % of revenue–––––14.5%12.5%18.0%13.8%
Depreciation and amortisation71010242431322930
Operating profit after depreciation29263046476065−1623
Other income000000000
Finance costs131515374357605961
Profit before tax1611159435−75−39
Tax4−253−112−91
Net profit1213106523−67−40
Net margin3.9%4.2%2.9%1.6%1.0%0.3%0.6%−17.3%−6.9%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 May
4748141,2601,3901,5071,6111,6871,798
Share capital5757595959595959
Reserves4177571,2021,3321,4481,5531,6291,740
258560448033117132
257282291513456560610690
21180595758738598
Total assets9421,1761,6101,9602,0212,2442,3822,587
4545055888821,1021,1241,2311,359
4886711,0221,0799191,1191,1511,228
Net debt228−99−366−9656−113−94−70
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 May
38091123291179214
522154170333197252
−77−102−6490−21−17
Receivables−30−171−4327−39−73
Inventories−108−11584−9964−10
Payables61183−1050−4667
Other working capital00016200
Tax paid−142−63−47−42−18−38
Capital spending108153211274214173
Free cash flow272−62−8817−3541
−317−120−119−192−154−198
−58−2−4−9346−29
Dividends paid233524292329
Shares bought back000000
Shares issued2800000
Net change in cash4−310770−13
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.IOL Chemicals and Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 May
₹0.15₹0.99₹8.42–₹15.24₹5.64₹4.77₹4.61₹3.44₹4.69
As stated that year₹0.75₹4.93₹42.11–₹76.21₹28.22₹23.84₹23.07₹3.44₹4.69
₹0.15₹0.99₹8.42–₹15.24₹5.64₹4.77₹4.61₹3.44₹4.69
–––₹0.60₹1.20₹0.80₹0.80₹1.00₹0.80₹1.00
––₹16.68₹28.60₹42.94₹47.36₹51.32₹54.89₹57.48₹61.26
Dividend payout–––4.7%7.9%14.2%16.8%21.7%23.3%21.3%
Shareholder yield––––−0.1%1.7%1.4%1.4%1.3%1.4%
Market cap at the year end (₹ crore)3544471,0721,0013,2342,0761,6602,1221,7952,136
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from. As stated that year and earnings per share are left blank for the year to Mar 2020: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.
RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 20 May
Revenue growth22.2%40.9%68.4%12.4%3.8%11.0%1.5%−3.8%−2.5%11.5%
Operating profit growth93.3%21.9%230.5%40.1%3.1%−56.7%−11.6%2.2%−12.7%33.1%
Net profit growth–554.8%754.5%52.6%23.0%−62.7%−15.5%−3.3%−25.4%36.4%
Earnings per share growth–557.3%754.2%––−63.0%−15.5%−3.2%−25.4%36.3%
––49.9%56.1%42.9%12.5%9.7%8.7%6.1%7.9%
–––6.2 pts−13.2 pts−30.4 pts−2.8 pts−1.0 pts−2.6 pts1.8 pts
From the net margin–––17.9 pts10.4 pts−28.5 pts−2.1 pts0.1 pts−2.0 pts1.4 pts
From asset turnover–––0.0 pts−14.0 pts−1.9 pts−0.9 pts−1.0 pts−0.7 pts0.3 pts
From borrowing–––−11.7 pts−9.6 pts0.0 pts0.2 pts0.0 pts0.2 pts0.1 pts
Return on capital employed––51.5%61.9%43.9%14.9%11.4%10.3%7.2%9.8%
Cash conversion––––85.4%55.0%88.0%214.7%176.9%155.7%
Interest cover1.11.57.325.794.825.711.010.58.813.0
Debt to equity––0.540.070.000.030.050.020.070.07
Receivable days––4354567983819095
Inventory days––66649895771119591
Payable days––4264799574123112118
Cash conversion cycle, days––6754747986697368
Working capital days––5856687885767874
Asset turnover––1.791.791.411.221.111.000.900.93
Assets per rupee of net worth––1.991.641.341.351.371.371.401.43
Sales per rupee of plant––4.104.073.863.902.952.321.801.99
Capital spending to depreciation––––2.783.544.584.362.972.16
Plant being built, % of plant in use––6.6%4.1%9.5%18.2%10.8%10.8%1.8%8.0%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
5.5%
Cash from operations against operating profit
79.7%
Measure10 years5 years3 years
Revenue growth, yearly rate14.8%3.3%1.5%
Profit growth, yearly rate–−20.9%−0.5%
Return on equity, average–9.0%7.6%
Return on capital employed, average–10.7%9.1%
Operating margin, average16.6%10.8%10.7%
Net margin, average9.0%6.2%5.7%
Asset turnover, average–1.030.94
Cash conversion cycle, days, average–7570
Interest cover, average19.913.810.8
Debt to equity, average–0.050.05

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations898684214
Cash from investing−784−544−198
Cash from financing−81−75−29
Capital spending1,025661173
Dividends paid1418229
Shares bought back000
Shares issued for cash000
Borrowings raised999915
Borrowings repaid127470

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––435–––
Altman Z-scorePublished threshold 1.81––5.456.129.54–––––
Beneish M-scorePublished threshold −1.78––––−1.92−0.79––––
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––27.4310.92––––
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.79–––
Receivables growth less revenue growthOur threshold 0 percentage points–––27.244.1545.40––––
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−2.4153.84−3.53––––
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−1.040.52−0.10––––
Assets under construction, years of additionsOur threshold 2 years of additions–––0.210.581.10––––
Effective tax ratePublished threshold 17.16 per cent22.8111.5029.5932.2522.20–––––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
6 Jul 2026CARE Ratings LimitedFund-based - LT-Working Capital LimitsCARE A+Review, Re-affirmStable200
6 Jul 2026CARE Ratings LimitedNon-fund-based - ST-BG/LCCARE A1+Review, Re-affirm500
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.